Dose Escalation Study of RSLV-132 in Subjects With Systemic Lupus Erythematosus
NCT ID: NCT02194400
Last Updated: 2015-12-09
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE1
32 participants
INTERVENTIONAL
2014-07-31
2015-11-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Placebo
Saline infusion
RSLV-132
0.3 - 10.0 mg/kg RSLV-132 weekly for 4 weeks
RSLV-132
0.3 - 10 mg/kg experimental drug
RSLV-132
0.3 - 10.0 mg/kg RSLV-132 weekly for 4 weeks
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
RSLV-132
0.3 - 10.0 mg/kg RSLV-132 weekly for 4 weeks
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
18 Years
70 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Resolve Therapeutics
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
James Posada, Ph.D.
Role: STUDY_CHAIR
Resolve Therapeutics
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Clinical Research of West Florida
Clearwater, Florida, United States
West Michigan Rheumatology
Grand Rapids, Michigan, United States
Altoona Center for Clinical Research
Duncansville, Pennsylvania, United States
Metroplex Clinical Research
Dallas, Texas, United States
Countries
Review the countries where the study has at least one active or historical site.
Related Links
Access external resources that provide additional context or updates about the study.
Resolve Therapeutics Website
Lupus Research Institute
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
132-02
Identifier Type: -
Identifier Source: org_study_id